anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Primary hyperparathyroidism is a common endocrine condition in which one or more of the four parathyroid glands in the neck releases too much parathyroid hormone (PTH). this leads to excess calcium in the blood and if untreated it can cause osteoporosis, kidney stone formation, deterioration of kidney function and disturbance in heart rhythm. Surgery to remove all or part of the affected gland(s) is expected to cure 95% of such patients. In current practice all such patients undergo localisation techniques using sestamibi scanning and neck ultrasonography to demonstrate the position of the enlarged/overactive parathyroid gland. These radiological tests are positive in some two thirds of patients, who can be operated through a minimally invasive procedure focused on the exact localisation pinpointed by the scans.

This study uses a procedure that does not require a surgical incision. Precise imaging of the parathyroid glands allows the exact position of the tumour to be found from outside the body. A High Intensity Focused Ultrasound beam produces heat, but only in a small specific area. Exact positioning of the ultrasound beam targets the tumour cells and kills them without harming the surrounding healthy tissues.
The invention relates to the technical field of gene engineering antibodies and especially relates to a gene engineering antibody specifically binding with a  B lymphocyte stimulator (Blys), a pharmaceutical composition containing the gene engineering antibody and a kit containing the gene engineering antibody. A heavy chain variable region of the gene engineering antibody contains amino acid sequences shown in the formulas of SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, or a light chain variable region of the gene engineering antibody contains amino acid sequences shown in the formulas of SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also provides the anti-Blys monoclonal antibody. The anti-Blys monoclonal antibody is produced by a cell strain having the preservation number of CGMCC No.7352. The anti-Blys monoclonal antibody has strong binding affinity to Blys, can inhibit Blys and IM9 cell surface receptors, can inhibit Blys-induced mouse spleen cell proliferation and can be used for treating Blys-related diseases. The anti-Blys monoclonal antibody has good antibody activity and good singularity, can be prepared easily and has wide clinical application and experiment application prospects.
PURPOSE: Primary progressive aphasia (PPA) is a neurodegenerative disorder characterized by worsening of speech and/or language. Script training intervention promotes automatized speech production via repeated practice of scripted content. This study evaluated the acceptability, feasibility, and effects of a modified version of Video-Implemented Script Training for Aphasia (VISTA) in the three PPA variants and compared outcomes by intervention modality (teletherapy vs. in person).
METHOD: Thirteen bilingual (Spanish-Catalan) participants were included (semantic variant, n = 5; logopenic variant, n = 5; nonfluent/agrammatic variant, n = 3; teletherapy, n = 7). Using a nonrandomized design, intervention was administered in participants' dominant language. Participants were trained on an individualized script twice per week, over 8 weeks. Performance on measures related to script accuracy, content, and subjective ratings of production quality was evaluated at baseline, immediately post, and at 3 and 6 months post-intervention.
RESULTS: No significant differences were observed on the basis of intervention modality. Participants demonstrated significant improvements from pre- to post-intervention in script production, synonym production, keywords, and global quality on the trained script. Maintenance was observed when comparing performance at post-intervention relative to 3- and 6-month follow-up for script and synonym production. Significant improvement in production quality of the untrained topic was observed following intervention. Different patterns of benefit were observed by PPA variant.
CONCLUSIONS: Modified VISTA was acceptable and effective across the three PPA variants, as evidenced by improvements on a broader array of outcome measures than those previously reported. Findings also provide further support for provision for teletherapy in individuals with PPA.
SUPPLEMENTAL MATERIAL: https://doi.org/10.23641/asha.26999326.
The present invention provides a crosslinking composition comprising the reaction product of an organohydrogensiloxane and a crosslinker in the presence of a hydrosilylation catalyst. The organohydrogensiloxanes comprise siloxy units having the average formula (I): (R) 4   3 SiO 1/2 )(R 4   2 SiO 2/2 ) a (R 1 R 4 SiO 2/2 ) b (R 4 HSiO 2/2 ) c (R 2 R 4 SiO 2/2 ) d (R 3 R 4 SiO 2/2 ) e ‑(R 4   3 Si‑O 1/2 )。R 1 And R 2 Each is an independently selected hydrogen atom or a substituted or unsubstituted hydrocarbyl group. R 3 Is a hydrogen atom or a group having at least one carboxyl group or a precursor of a carboxyl group. R 4 Is an independently selected substituted or unsubstituted hydrocarbyl group. In addition, a is greater than or equal to 0, b is greater than or equal to 0, c is greater than or equal to 1, d is greater than or equal to 0, and e is greater than or equal to 1. The crosslinker has at least two aliphatic unsaturated hydrocarbon groups. The method of forming the crosslinked composition comprises the steps of: providing an organohydrogensiloxane and a crosslinker, and combining said organohydrogensiloxane and crosslinker in the presence of said hydrosilylation catalyst to form said crosslinked composition. The invention provides a cosmetic composition comprising the crosslinking groupA composition and at least one cosmetic component.
FIELD: organic chemistry, chemical-pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to preparing water-soluble preparations of acetylsalicylic acid. Invention proposes novel water-soluble analog of acetylsalicylic acid of the formula:   where n : m = (5:1)-(1:5). Analog is synthesized by chemical immobilization of acetylsalicylic acid on copolymer of N-vinylpyrrolidone with N-(glycidyl)-vinyl-γ-amino-butyric acid. This polymer is prepared by treatment of polyvinyl-pyrrolidone with chloromethyloxirane in the presence of catalyst that results to opening part of pyrrolidone cycles to form structure of N-vinyl-γ-aminobutyric acid and formation of by-side chains carrying reactive glycidyl groups. New analog shows the enhanced analgetic, anti-inflammatory, antipyretic and thrombolytic activity and reduced gastrotoxicity and nephrotoxicity. New analog of acetylsalicylic acid in the dose containing 75 mg of substance does not exhibit the damage effect on stomach mucosa that is typical for equal dose of acetyl- -salicylic acid. EFFECT: improved properties of analog. 3 cl, 2 tbl, 5 ex
BACKGROUND: Few studies have addressed the performance and diagnostic accuracy of laboratory-based markers for fibrosis prediction in chronic hepatitis B (CHB) patients yielding heterogeneous results. We aimed to study the performance of the FIB-4 and neutrophil-to-lymphocyte ratio (NLR) markers for the differentiation between significant and non-significant hepatic fibrosis in real-life practice.
METHODS: We prospectively recruited CHB patients attending the hepatology clinic to undergo shear wave elastography (SWE) and blood tests. The predictive accuracy of FIB-4 and NLR for liver fibrosis was assessed by receiver operating characteristics (ROC) analysis.
RESULTS: Overall, 174 fully characterized CHB patients with an average age of 50.2±11.2 (29-86 years) and a male predominance (65.2%) were included. Of these, 23% had significant fibrosis (≥F2) per SWE (>7.1KPA). A significant and linear correlation was found between the SWE score and FIB-4 values (r=0.572; P<0.001). A lower cut-off of 1.43 has yielded an AUROC of 0.76, with a sensitivity of 68.8%, specificity of 79.8%, diagnostic accuracy of 78.5%, and NPV of 96%. On the contrary, NLR values were similar between significant and minimal fibrosis and were not found to be correlated with significant fibrosis (r=0.54, P=0.39).
CONCLUSIONS: FIB4 has a moderate performance and may have a valuable role in excluding significant fibrosis in CHB patients in daily practice.
This is a single-center, open-labelled study. Twenty four Chinese adult volunteers who schedule for gastrointestinal endoscopy will be enrolled and will be not allowed to take products containing grapefruit, fruit juice, tea, coffee, wine and other foods or drinks containing caffeine, xanthine and alcohols at least 14 days before the gastrointestinal endoscopes. In addition, smoking is also prohibited. Screen will be performed any day between 3 and 14 days prior to the gastrointestinal endoscopes. Feces, saliva and 4 ml whole blood samples will be collected from these participants 3 days before gastrointestinal endoscopes for the detection of bacterial diversity, metabolic enzymes, transporter-related genotypes and bile acids. Afterwards, participants will undergo painless gastroscopy. Meanwhile, gastric juice, mucosal tissue from stomach, duodenum, jejunum, ileum, colon will be collected. The total number of mucosal tissue no more than 10.
Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
OBJECTIVE: The surgical treatment of Eagle syndrome involves an intra- or extraoral approach. This systematic review set out to consolidate current knowledge on the prevalence of complications associated with intraoral and external approaches.
METHODS: Seven main electronic and two gray literature databases were searched. Studies were blindly selected by two reviewers based on pre-defined eligibility criteria. Studies evaluating any type of complication in the treatment of Eagle syndrome were considered eligible. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for studies reporting prevalence data, case reports, and case series. The Comprehensive Meta-Analysis software (Software version 3.0 - Biostat, Englewood, NJ, USA) was used to perform all meta-analyses.
RESULTS: Out of 1728 articles found on all databases, 36 were included for qualitative analysis. Twenty were included for quantitative analysis and meta-analysis.
CONCLUSION: In this study, the highest rate of complications was found in the intraoral approach.
FIELD: medicine. SUBSTANCE: desired product has essential formula CHNO, its melting point being 181-182 C (with decomposition). Hydrazide of p-toluyl acid is used as reagent 1, maleic anhydride being used as reagent 2. Reaction is carried out in the medium of acetonitrile. Yield of desired product is 98 %. EFFECT: improves quality of desired product. 1 tbl
Evidence-Based Medicine has little consideration for mechanisms and philosophers of science and medicine have recently made pleas to increase the place of mechanisms in the medical evidence hierarchy. However, in this debate the notions of mechanisms seem to be limited to 'mechanistic processes' and 'complex-systems mechanisms,' understood as 'componential causal systems'. I believe that this will not do full justice to how mechanisms are used in biological, psychological and social sciences and, consequently, in a more biopsychosocial approach to medicine. Here, I propose, following (Kuorikoski, 2009), to pay more attention to 'abstract forms of interaction' mechanisms. The present work scrutinized review articles on depression and medically unexplained pain, which are considered to be of multifactorial pathogenesis, for their use of mechanisms. In review articles on these disorders there seemed to be a range of uses between more 'abstract forms of interaction' and 'componential causal system' mechanisms. I therefore propose to expand the notions of mechanisms considered in medicine to include that of more 'abstract forms of interaction' to better explain and manage biopsychosocial disorders.
BACKGROUND: Severe asthma places a large burden on patients and society. The characteristics of patients with severe asthma in the Chinese population remain unclear.
METHODS: A retrospective review was conducted in patients with severe asthma. Demographic and clinical data were collected. Patients were grouped according to phenotypes in terms of exacerbations, body mass index (BMI) and fixed airway obstruction (FAO) status, and the characteristics of different groups were compared. Comorbidities, factors that influence asthma phenotypes, were also analyzed in the study.
RESULTS: A total of 228 patients with severe asthma were included in our study. They were more likely to be overweight or obese. A total of 41.7% of the patients received GINA step 5 therapy, and 43.4% had a history of receiving regular or intermittent oral corticosteroids (OCS). Severe asthmatic patients with comorbidities were prone to have more asthma symptoms and decreased quality of life than patients without comorbidities. Patients with exacerbations were characterized by longer duration of asthma, poorer lung function, and worse asthma control. Overweight or obese patients tended to have more asthma symptoms, poorer lung function and more asthma-related comorbidities. Compared to patients without FAO, those in the FAO group were older, with longer duration of asthma and more exacerbations.
CONCLUSION: The existence of comorbidities in patients with severe asthma could result in more asthma symptoms and decreased quality of life. Patients with exacerbations or with overweight or obese phenotypes were characterized by poorer lung function and worse asthma control. Patients with FAO phenotype tended to have more exacerbations.
PCT No. PCT/JP93/01724 Sec. 371 Date May 26, 1995 Sec. 102(e) Date May 26, 1995 PCT Filed Nov. 25, 1993 PCT Pub. No. WO94/12661 PCT Pub. Date Sep. 6, 1994An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.
This invention belongs to infection correlative medicine region, supplies a dihydroisoxazol ramification and its pharmacy receivable salt. The general formula is described as (1), and R1 represents hydrogen or C1 to C6 alkyl. R3 represents hydrogen or single substituted or polysubstituted C1 to C6 alkyl. R4 represents single substituted or polysubstituted halogen. R5 represents C1 to C6 alkyl, or single substitute or polysubstituted halogen C1 - C6 alkyl.  Definition of  R6, R7 and R8 is described in specification.This invention also relates to the antibacterial using of this kind compound and its pharmacy receivable salt.
The invention discloses a medicinal composition for treating rectal prolapse. The rectal prolapse is mainly caused by weak pelvic floor tissues such as relax of anal sphincter, continual long-term intra-abdominal pressure increase caused by various reasons, deficiency of qi and blood in theory of traditional Chinese medicine and collapse from qi deficiency. At present, the treatment method is mostly western medicine treatment, and sticking of adhesive tapes or injection and operation are adopted, but the defects that the treatment process is complex and long, the pain of patients cannot be timely relieved and the like exist. External powder prepared from gallnut, keel, pomegranate bark and alum is applied to an affected part. Through 49 cases of clinical use, the cure rate is 85.7 percent. The composition is prepared from Chinese medicaments, is easy to prepare, remarkable in treatment effect, convenient to use, short in treatment period and low in treatment cost, has an effect on complete prolapse and incomplete prolapse, simplifies the treatment, reduces the treatment cost of the patients, and is definite in treatment effect.
Certain embodiments of the present invention provide methods and systems for clinical workflow using gesture recognition. Certain embodiments provide a method for gesture-based interaction in a clinical environment. The method includes detecting a gesture made on a sensor surface. The method also includes determining a pressure applied to make the gesture. The method further includes mapping the gesture and the pressure to a healthcare application function. The pressure modifies the healthcare application function corresponding to the gesture. Certain embodiments provide a gesture detection system including a sensor surface configured to detect a gesture made. The system further includes a pressure sensor configured to detect a pressure applied when making the gesture on the sensor surface. The system also includes a processor configured to identify the gesture and translate the gesture to a healthcare application function. The pressure modifies the healthcare application function corresponding to the gesture.
Severe neurologic adverse reactions have been reported with the use of ARRANON®. These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome [see Warnings and Precautions (5.1)].

Full recovery from these adverse reactions has not always occurred with cessation of therapy with ARRANON. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with ARRANON. Discontinue ARRANON for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or greater [see Warnings and Precautions (5.1)].
Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
Herbaspirillum spp. is a common environmental bacterium usually found in soil, plant roots, and water. It is rarely associated with infection in immunocompromised patients, and rarely reported infections in immunocompetent patients. We report the first case of a Herbaspirillum huttiense bacteraemia in a non-neutropenic home haemodialysis patient. A 57-year-old male presented to our hospital with a 3-day history of malaise, fevers, rigours, and anorexia following dialysis through his central line. On examination, he was pyrexic (temperature 38.7°C) with splinter haemorrhages noted, but no other signs of infection were present. Blood cultures revealed a polymicrobial infection, with Serratia liquefaciens and Corynebacterium jeikeium isolated from the central line and Herbaspirillum sp. was isolated from both the central line and a peripheral culture. A later peripheral blood culture following central line removal isolated Herbaspirillum huttiense. Regular biological testing of his home water supply and dialysate detected no colony forming units of non-fermenting gram-negative bacilli. He was initially treated with ceftriaxone and vancomycin initially, followed by ertapenem and vancomycin. Intravenous antibiotics were ceased following 5 days after central line removal and he made an uneventful recovery.
The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
PURPOSE: Many factors have been associated with health-related quality of life (HRQOL), and researchers often have tried to rank these contributing factors. Variable importance quantifies the net independent contribution of each individual predictor in a set of predictors to the prediction accuracy of the outcome. This study assessed relative importance (RI) of selected contributing factors to respondents' physically unhealthy days (PUD), mentally unhealthy days (MUD), activity limitation days (ALD), and EuroQol EQ-5D index derived from the Healthy Days measures (dEQ-5D).
METHODS: Using data from the 2021 Behavioral Risk Factor Surveillance Systems (BRFSS), we estimated the RI of seven socio-demographics and seventeen chronic conditions and risk behaviors. A variable's importance was measured as the average increase in the coefficient of determination after adding the variable to all possible sub-models.
RESULTS: After controlling for socio-demographics, arthritis and no physical activity were the most important variables for PUD with a RI of 10.5 and 10.4, respectively, followed by depression (RI = 8.5) and COPD (RI = 8.3). Depression was the most important variable for MUD with RI = 23.0 while all other 16 predictors had a RI < 7.0. Similar results were observed for ALD and dEQ-5D: depression was the most important predictor (RI = 16.3 and 15.2, respectively), followed by no physical activity, arthritis, and COPD (RI ranging from 7.1 to 9.2).
CONCLUSION: This study quantified and ranked selected contributing factors of HRQOL. Results of this analysis also can be used to validate HRQOL measures based on domain knowledge of HRQOL.
Bleeding is the most common complication encountered during eptifibatide therapy. Administration of eptifibatide is associated with an increase in major and minor bleeding, as classified by the criteria of the Thrombolysis in Myocardial Infarction Study group (TIMI) [see Adverse Reactions (6.1)]. Most major bleeding associated with eptifibatide has been at the arterial access site for cardiac catheterization or from the gastrointestinal or genitourinary tract. Minimize the use of arterial and venous punctures, intramuscular injections and the use of urinary catheters, nasotracheal intubation and nasogastric tubes. When obtaining intravenous access, avoid non-compressible sites (e.g., subclavian or jugular veins). 

Use of Thrombolytics, Anticoagulants and Other Antiplatelet Agents 

Risk factors for bleeding include older age, a history of bleeding disorders and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs and P2Y12 inhibitors). Concomitant treatment with other inhibitors of platelet receptor glycoprotein (GP) IIb/IIIa should be avoided. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT [see Dosage and Administration (2)]. 

Care of the Femoral Artery Access Site in Patients Undergoing Percutaneous Coronary Intervention (PCI) 

In patients undergoing PCI, treatment with eptifibatide is associated with an increase in major and minor bleeding at the site of arterial sheath placement. After PCI, eptifibatide infusion should be continued until hospital discharge or up to 18 to 24 hours, whichever comes first. Heparin use is discouraged after the PCI procedure. Early sheath removal is encouraged while eptifibatide is being infused. Prior to removing the sheath, it is recommended that heparin be discontinued for 3 to 4 hours and an aPTT of < 45 seconds or ACT <150 seconds be achieved. In any case, both heparin and eptifibatide should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge. If bleeding at access site cannot be controlled with pressure, infusion of eptifibatide and heparin should be discontinued immediately.